Table 2. Eligible drugs, systematic review and meta-analysis of generic direct-acting agents for treating hepatitis C.

Drug	Formulation	Brand name
Sofosbuvir	Tablets containing 400 mg	Sovaldi®
Simeprevir	Capsules containing 150 mg	Olysio®
Daclatasvir	Tablets containing 30 or 60 mg	Daklinza®
Sofosbuvir–ledipasvir combination	Tablets containing 400 mg of sofosbuvir and 90 mg of ledipasvir	Harvoni®
Sofosbuvir–velpatasvir combination	Tablets containing 400 mg of sofosbuvir and 100 mg of velpatasvir	Epclusa®
Grazoprevir–elbasvir combination	Tablets containing 100 mg of grazoprevir and 50 mg of elbasvir	Zepatier®